This Multibagger Chemical Inventory is in focus because it jumped over 5 % following its Q4FY25 Outcomes with sturdy Web Revenue progress, dividend announcement, and Acquisition Replace value 7.50 Crore from the Firm.
Share Worth Motion
With a market capitalization of Rs. 23,921 Crore, the inventory of Himadri Speciality Chemical opened at Rs. 491.30, up 2.56 % from yesterday’s shut, and after opening, it made a excessive of Rs. 505, up 5.53 %. Moreover, the Yearly return for the inventory is 39 %, and the previous 5-year return is a powerful 933 %.
Monetary Highlights
The corporate reported a 3.56 % YoY lower in income from Rs. 1,177 Crore in Q4FY24 to Rs. 1,135 Crore in Q4FY25. On a QoQ foundation, the corporate reported a marginal lower of 0.52 % in income from Rs. 1,141 Crore within the earlier quarter.
Their Web revenue noticed a rise of 34.78 % YoY from Rs. 115 Crore to Rs. 155 Crore for a similar interval. On a QoQ foundation, the corporate reported a rise of 10.12 % in Web revenue from Rs. 141 Crore within the earlier quarter.
Additionally learn: Tata metal & 4 different metal shares to learn as India imposes 12% safeguard obligation on metal imports
Acquisition and Dividend Announcement
The board authorized the acquisition of a 100% stake in Elixir Carbo Non-public Restricted for a complete consideration of Rs. 7.50 Crore in Money by buying fairness shares of the goal firm. On completion of buy, it’s going to develop into a (WOS) Wholly Owned Subsidiary of the Firm.
The board has additionally really useful a closing dividend of Rs. 0.60 per fairness share of Rs. 1, or 60 % of the face worth, which will likely be topic to the approval of the shareholders of the Firm.
In regards to the Firm
Established in 1990, Himadri Speciality Chemical or HSCL is a number one speciality Carbon Firm, with a robust presence in each home and international markets. It operates throughout a number of verticals, together with coal tar pitch, superior carbon supplies, carbon black, naphtalene derivatives, and specialty oils.
Written By Abhishek Das
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/score businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the creator usually are not responsible for any losses precipitated on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
